Navigation Links
Mast Therapeutics To Present At The Piper Jaffray 27th Annual Healthcare Conference
Date:11/24/2015

SAN DIEGO, Nov. 24, 2015 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, heart failure and stroke, today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the Piper Jaffray 27th Annual Healthcare Conference on Tuesday, December 1, 2015 at 4:30pm Eastern Time at the New York Palace hotel in New York City.

Interested parties can access a live audio webcast of the fireside chat on the Mast Therapeutics web site at www.masttherapeutics.com. An archived presentation will be available on the web site for 30 days.

About Mast Therapeutics
Mast Therapeutics, Inc. is a publicly traded biopharmaceutical company headquartered in San Diego, California.  The Company is leveraging its MAST platform, derived from over two decades of clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers, to develop vepoloxamer (also known as MST-188), its lead product candidate, for serious or life-threatening diseases and conditions typically characterized by impaired microvascular blood flow and damaged cell membranes.  The Company is also developing AIR001, a sodium nitrite solution for inhalation via nebulizer, for the treatment of heart failure with preserved ejection fraction (HFpEF).

Vepoloxamer is an investigational new drug being tested in a pivotal Phase 3 study called EPIC for the treatment of vaso-occlusive crisis in patients with sickle cell disease and in a Phase 2 study for the treatment of patients with chronic heart failure.  AIR001 is an investigational new drug being tested in two institution-sponsored Phase 2a studies in patients with HFpEF. More information can be found on the Company's web site at www.masttherapeutics.com. (Twitter: @MastThera)

Mast Therapeutics™ and the corporate logo are trademarks of Mast Therapeutics, Inc.

Forward Looking Statements
Mast Therapeutics cautions you that statements included in this press release or made during the presentation announced hereby that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements may include, but are not limited to, statements relating to prospects for successful development and commercialization of, and patent protection for, the Company's investigational drugs, including vepoloxamer and AIR001, and anticipated timing of achievement of development milestones, such as commencement and completion of clinical studies or regulatory activities, and of announcement of study data. Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: the uncertainty of outcomes in ongoing and future studies of the Company's product candidates and the risk that its product candidates, including vepoloxamer, may not demonstrate adequate safety, efficacy or tolerability in one or more such studies, including EPIC and the Phase 2 study of vepoloxamer in chronic heart failure; delays in the commencement or completion of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects, manufacturing sufficient quantities of clinical trial material, being subject to a "clinical hold," and/or suspension or termination of a clinical study, including due to patient safety concerns or lack of funding; the risk that, even if planned clinical studies are successful, the FDA or other regulatory agencies may determine they are not sufficient to support a new drug application; the potential that, even if clinical studies of a product candidate in one indication are successful, clinical studies in another indication may not be successful; the potential for additional nonclinical or clinical studies to be required prior to initiation of a planned clinical study; the Company's reliance on contract research organizations (CROs), contract manufacturing organizations (CMOs), and other third parties to assist in the conduct of important aspects of development of its product candidates, including clinical studies, manufacturing, and regulatory activities for its product candidates, and that such third parties may fail to perform as expected; the risk that the Company may be required to repay its outstanding debt obligations at a time that could be detrimental to its financial condition, operations and/or business strategy; the Company's ability to obtain additional funding on a timely basis or on acceptable terms, or at all; the potential for the Company to delay, reduce or discontinue current and/or planned development activities, including clinical studies, partner its product candidates at inopportune times or pursue less expensive but higher-risk and/or lower return development paths if it is unable to raise sufficient additional capital as needed; the risk that, even if the Company successfully develops a product candidate in one or more indications, it may not realize commercial success and may never achieve profitability; the risk that the Company is not able to adequately protect its intellectual property rights, through patents or otherwise, and prevent competitors from duplicating or developing equivalent versions of its product candidates or that the use or manufacture of its products or product candidates infringe the proprietary rights of others; and other risks and uncertainties more fully described in the Company's press releases and periodic filings with the Securities and Exchange Commission. The Company's public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. Mast Therapeutics does not intend to revise or update any forward-looking statement set forth in this press release or made during the presentation announced hereby to reflect events or circumstances arising after the date when made, except as may be required by law. 

Logo - http://photos.prnewswire.com/prnh/20120612/LA22456LOGO-a


'/>"/>
SOURCE Mast Therapeutics
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
2. Novelos Therapeutics Provides Product Pipeline Update
3. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
4. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
6. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
7. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
8. The Leukemia & Lymphoma Society, Valor Biotherapeutics and ImmunGene Create Partnership to Advance Novel Therapy for Non-Hodgkin Lymphoma Patients
9. Advanced Prenatal Therapeutics - Using Targeted Apheresis to Treat Preeclampsia
10. Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML)
11. Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/19/2019)... SEATTLE (PRWEB) , ... July 19, 2019 , ... ... excited to announce the hiring of Chris Whaley as Senior Vice President of ... ways to make the patient experience better using cloud technology. , As a ...
(Date:7/19/2019)... HILLS, Calif. (PRWEB) , ... July 19, 2019 , ... ... Levin, L.M.F.T., is proud to announce the expansion of The Missing Peace with the ... for the Brain opens its doors July 19, 2019. , The Missing ...
(Date:7/19/2019)... ... 2019 , ... The San Francisco employment law attorneys ... lawsuit against Hospital Couriers Nevada, LLC, for allegedly failing to provide their workers ... periods. The class action also alleges that Hospital Couriers Nevada, LLC, failed to ...
Breaking Medicine Technology:
(Date:7/19/2019)... ... July 19, 2019 , ... Medtelligence , the ... as Senior Director of Education Strategy. Clem has extensive experience gained through key ... with physician experts on comprehensive educational programming, Megan brings a level of excellence ...
(Date:7/18/2019)... ... 2019 , ... LEAD Hospitality Group is preparing to participate in the 36th ... The event is scheduled to take place August 17, 2019 and will kick off ... the King & Queen Buildings. LEAD Hospitality Group will be attending with their running ...
(Date:7/18/2019)... LA JOLLA, Calif. (PRWEB) , ... July 18, 2019 , ... ... insight into their future children, announces a new publication titled, “ Accurate Fetal Sex ... Pregnancy & Child Birth. In the study, DNA blood samples were collected from 108 ...
(Date:7/17/2019)... Ky. (PRWEB) , ... July 17, 2019 , ... ... awarded to Eastern Kentucky University’s online Family Nurse Practitioner program. The honor is ... quality in distance education. , The Catalyst Awards honor institutions from around ...
(Date:7/17/2019)... ... July 17, 2019 , ... ICD10monitor, an online ... coding set, is launching an exclusive educational webcast subscription service featuring 40 original ... officials announced this week. , The ICD10monitor webcast portfolio already includes sought-after ...
Breaking Medicine News(10 mins):